NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces IRB Approval for Acute Alcohol Intoxication Study
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has received approval for its METAL-2 trial to be conducted in the United States. The approval came from the institutional review board (“IRB”). With the approval, FSD Pharma can now begin to plan execution of the clinical study and to recruit participants for the clinical trial. “We are excited that the METAL-2 trial has received IRB approval, allowing us to advance this clinical study in the United States,” said FSD Pharma vice…







